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The complement fragments C3a and C5a were purified from zymosan-activated human serum by column chromatograph- 
ic procedures after the bulk of the proteins had been removed by acidic polyethylene glycol precipitation. In the isolated 
in situ perfused rat liver C3a increased glucose and lactate output and reduced flow. Its effects were enhanced in the 
presence of the carboxypeptidase inhibitor DL-mercaptomethyl-3-guanidinoethylthio-propanoic acid (MERGETPA) 
and abolished by preincubation of the anaphylatoxin with carboxypeptidase B or with Fab fragments of an anti-C3a 
monoclonal ntibody. The C3a effects were partially inhibited by the thromboxane antagonist BM13505. C5a had no 
effect. It is concluded that locally but not systemically produced C3a may play an important role in the regulation of 
local metabolism and hemodynamics during inflammatory processes in the liver. 
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1. INTRODUCTION 
Pyrogenic substances such as cell wall particles 
from yeast (zymosan) [1,2] and lipopolysac- 
charides from Gram negative bacteria [3] have 
been shown to increase glucose and lactate output 
and to reduce perfusion flow or increase portal 
pressure, respectively, in the perfused rat liver. 
Similar alterations were observed after infusion of 
heat-aggregated immunoglobulins which resemble 
immune complexes in their biological properties 
[4]. Rabbit serum that had been complement ac- 
tivated by incubation with zymosan was shown to 
induce the release of thromboxane from rabbit 
livers [5]. The complement fragments C3a and C5a 
have been reported to cause contraction of smooth 
muscle [6] and human C5a was shown to elicit 
vasoconstriction i  the kidneys of Munich Wistar 
rats [7]. 
It was the aim of this study to evaluate whether 
these peptides might affect the metabolism and the 
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hemodynamics of the liver. Complement-activated 
human serum and the purified anaphylatoxin C3a 
but not C5a were found to increase glucose and 
lactate output and to decrease flow in the perfused 
rat liver. 
2. MATERIALS AND METHODS 
2.1. Materials 
All chemicals were reagent grade and from commercial 
sources. The Merck glucose system was purchased from Merck 
(D-6100 Darmstadt). Lactate dehydrogenase and glutamic 
pyruvic transaminase were from Boehringer (D-6800 Mann- 
heim). The thromboxane antagonist BM13505 was a gift of this 
company, e-Amino caproic acid and carboxypeptidase B were 
obtained from Sigma (D-8024 Deisenhofen). MERGETPA was 
purchased from Calbiochem (D-6000 Frankfurt) and 
polyethylene glycol 6000 (PEG) from Serva (D-6900 
Heidelberg). CM-52 Cellulose was obtained from Whatman 
(UK-ME 14 2LE Kent) and Sephadex G50 fine from Pharmacia 
(D-7800 Freiburg). Dialysis tubing with a cut off of 3.5 kDa 
was bought from Reichelt (D-6900 Heidelberg). 
2.2. Animals 
Male Wistar rats (140-180 g, Winkelmann, D-4791 Borchen) 
were kept on a 12 h day-night rhythm, light from 7 a.m. to 7 
p.m., with free access to water and food (standard rat diet, 
Ssniff, D-4770 Soest). All experiments were started between 9
and 10 a.m. 
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2.3. Isolation of human C3a and C5a 
Human C3a and C5a were purified using a modified method 
based on a previous brief description of the C5a purification 
[8]. Human serum obtained from healthy blood donors through 
the transfusion service of the university hospital was activated 
with boiled yeast cells (zymosan) in the presence of 1 M e- 
aminocaproic acid for 1 h at 37°C. All subsequent s eps were 
carried out at 0 -4°C.  The bulk of the proteins was precipitated 
by adding 10070 (w/v) PEG and titrating the incubation mixture 
to pH 4.0 with 8 N HC1. Zymosan and precipitated proteins 
were removed by centrifugation at 27000 × g for 30 rain. The 
supernatants were then frozen at - 20°C overnight and the cen- 
trifugation repeated after thawing the sample the next morning. 
The clear supernatant was diluted about fivefold with 50 mM 
ammonium formate, pH 4.5, to reach a conductivity of about 
l0 mS/cm. This sample was applied to a CM-52 column that 
was equilibrated with the same buffer. The column was washed 
with 400 ml of the equilibration buffer and eluted with 800 ml 
of a linear NaC1 gradient from 0 to 0.8 M in the same buffer 
(fig.l). C5a and C3a were detected in the eluate employing 
ELISA procedures [8,9]. The fractions with the highest contents 
of the respective peptides were pooled for further purification. 
The C5a pool was lyophilized and redissolved in 8 ml of 
25 mM Tris-HCl, pH 7.4. It was chromatographed on 
Sephadex G50 fine equilibrated with the same Tris-HC1 buffer 
containing 154 mM NaC1 which was also used for elution 
(fig. 1). The C5a-containing fractions were pooled and stored at 
- 20oc. 
The C3a pool was dialyzed against 10 mM sodium-acetate, 
pH 5.0, using a dialysis tubing with a 3.5 kDa cutoff and ap- 
plied to CM-52 cellulose quilibrated with the same buffer. The 
proteins were eluted with the equilibration buffer containing 
0.6 M NaC1. The C3a-containing fractions were pooled and 
stored at -20°C .  
The purity of the C3a and C5a preparations was ascertained 
by standard SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) [10]. 
2.4. Antibodies against C3 and C5a 
Monoclonal antibodies pecific for C3a or C5a, respectively, 
were produced as described [8,11]; Fab fragments from the 
anti-C3a antibodies were obtained by papain-cleavage. They 
were purified by FPLC anion-exchange chromatography on 
Mono-Q [121. 
2.5. Liver perfusion 
Rats were anaesthetized by intraperitoneal injection of pen- 
tobarbital (60 mg/kg body wt). The liver was perfused in situ 
as described previously [13] using an erythrocyte-free Krebs- 
Henseleit bicarbonate buffer, which contained 5 mM glucose, 
2 mM lactate and 0.2 mM pyruvate and was equilibrated with 
95°7o 021507o COz (v/v). After a preperfusion period of 30 min 
the experiment was started. At the times indicated purified C3a 
or C5a were infused. The flow was determined by quantitating 
the perfusate fractions collected at 1 rain intervals. 
2.6. Metabolite assays 
Glucose was determined in the perfusate using a commercial 
test kit (Merck Glucose System) based on the glucose 
dehydrogenase method [14]. Lactate was measured in a combin- 
ed optical test using lactate dehydrogenase and glutamic pyruvic 
transaminase [15]. 
3. RESULTS 
3.1. Purification of the anaphylatoxins 
Chromatography of zymosan-activated human 
serum on CM-52 cellulose after acidic PEG 
precipitation resulted in a good separation of C3a 
and C5a. C5a co-eluted with the major protein 
fraction at 0.25 M NaCl; C3a eluted, separated 
from the major protein peak, at about 0.6 M NaCl 
(fig.lA). The CSa fractions were lyophilized, 
redissolved in a small volume of buffer and 
chromatographed on Sephadex G-50 fine. On this 
column most of the protein eluted before the CSa 
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Fig.1. Purification of the anaphylatoxins C3a and C5a. (A) 
Chromatography of the supernatant after acidic PEG 
precipitation of zymosan-activated human serum on 
CM52-cellulose (5 cm diameter, 200 ml bed volume, 200 ml/h 
flow rate, 4 ml fractions). (B) Chromatography of the pooled 
and lyophilized C5a fractions from panel A on Sephadex GS0 
(2.5 cm diameter, 440 ml bed volume, 16 ml /h  flow rate, 4 ml 
fractions). (C) Rechromatography of the dialyzed C3a fractions 
from panel A on CM52-cellulose (2.5 cm diameter, 30 ml bed 
volume, 50 ml /h flow rate, 2.5 ml fractions). 
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peak (fig.lB). The peak fractions of C5a were 
pooled; the preparation contained 6#g C5a/ml 
and one major contaminant, which migrated in the 
SDS-PAGE as a 69 kDa band and was assumed to 
be albumin. Rechromatography of the dialyzed 
C3a fractions on CM-52 cellulose in a small col- 
umn (fig. 1C) yielded a C3a preparation that had a 
concentration of 35 #g C3a/ml and was free of 
contaminants detectable by SDS-PAGE. 
3.2. Actions of C3a and C5a on liver metabolism 
and hemodynamics 
In perfused rat livers infusion of human serum 
at a rate of about 7°7o of the perfusion flow for 
2 min caused a slight increase in glucose and lac- 
tate output and a slight decrease in perfusion flow. 
Preincubation of the serum with zymosan for 1 h 
at 37°C led to a marked enhancement of these ef- 
fects (not shown). 
Infusion of purified human C3a for 2 min to a 
final concentration of 3 #g/ml  (fig.2A) caused an 
increase in glucose and lactate output that reached 
a maximum 3 min after the start of the infusion 
and returned to preinfusion levels during the 
following 3 min. C3a also elicited a decrease in 
flow which reached its lowest values 2 min after 
the start of the infusion. After cessation of the in- 
fusion the flow slowly recovered to reach preinfu- 
sion levels within 4 min. 
C5a (0.5#g/ml) did not influence liver 
metabolism or hemodynamics in either the absence 
or the presence of 0.1 mM of the carboxypeptidase 
inhibitor MERGETPA [16] (not shown). The 
biological activity of the C5a used had been ascer- 
tained by its induction of ATP release from 
guinea-pig platelets. 
3.3. lncrease of the metabolic and hemodynamic 
actions of C3a by inhibition of hepatic 
carboxypeptidase 
The alterations caused by C3a could be almost 
totally prevented by preincubation of C3a at 37°C 
for 1 h with carboxypeptidase B, which inactivates 
C3a through the removal of the C-terminal 
arginine residue [17] generating C3a-desArg 
(fig.2B). Infusion of C3a together with a final con- 
centration of 0.1 mM of MERGETPA resulted in 
a marked enhancement of both glucose and lactate 
output and flow reduction (not shown). In the 
presence of MERGETPA the increase in glucose 
and lactate release and the decrease in flow caused 
by 1 #g C3a/ml infused for only 30 s were larger 
than the changes elicited by 3 #g C3a/ml applied 
for 2 min in the absence of MERGETPA (fig.3A 
vs fig.2A). 
In the presence of MERGETPA infusion of 
about 0.4 #g C3a/ml for 30 s caused already max- 
imal alterations, while the minimal concentration 
of C3a that was found to reduce flow and to in- 
crease lactate output was 0.08 #g/ml.  An increase 
in glucose output could still be observed at 
0.04 #g/ml (not shown). 
3.4. Inhibition of the metabolic and hemodynamic 
actions of C3a 
Preincubation of C3a at pH 7.4 in the presence 
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Fig.2. Metabolic and hemodynamic alterations in perfused rat 
liver after infusion of  the anaphylatoxins C3a and C3a-desArg. 
Livers were perfused in situ with Krebs-Henseleit bicarbonate 
buffer containing 5 mM glucose, 2 mM lactate and 0.2 mM 
pyruvate. Substrate balance is given by (posthepatic 
concentrat ion-  prehepatic oncentration in #mol × ml -~) × 
flow in ml x min -J × g liver - l .  (A) C3a in a 20 mM Hepes 
buffer, pH 7.4, with 5 mM glucose and 2 mM lactate was 
infused to a final concentration of about 3 #g/ml  for 2 min. (B) 
Same experiment as in panel A, except that the C3a solution 
was preincubated for 1 h at 37°C with carboxypeptidase B 
(10#g/ml) .  Values are means _+ SE of the number of 
experiments given in parentheses. 
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Fig.3. Metabolic and hemodynamic alterations in perfused rat 
liver after infusion of the anaphylatoxin C3a in the presence of 
the carboxypeptidase inhibitor MERGETPA with and without 
pretreatment of C3a with anti-C3a Fab fragments. The 
experimental conditions were the same as in fig.2. (A) C3a was 
incubated overnight at 4°C in 20 mM Hopes buffer, pH 7.4, 
containing 5 mM glucose, 2 mM lactate and 1 mM 
MERGETPA.  This mixture was infused to a final 
concentration of 1 ,ug C3a/ml and 0.1 mM MERGETPA for 
30 s. (B) Same conditions as in panel A, except that C3a was 
preincubated in a Hepes buffer containing in addition a 
threefold molar excess of Fab fragments of a neutralizing 
monoclonal antibody against C3a. Values are means +_ SE of 
the number of experiments given in parentheses. 
threefold molar excess of Fab fragments of a 
monoclonal antibody, which neutralized C3a ac- 
tivity in a guinea-pig platelet ATP-release test (Op- 
permann, unpublished results), abolished almost 
entirely the C3a-mediated stimulation of glucose 
and lactate output as well as the reduction in perfu- 
sion flow (fig.3B). C3a incubated overnight under 
the same conditions without Fab fragments re- 
mained biologically active (fig.3A). 
The reduction of perfusion flow by C3a could be 
inhibited almost completely by the thromboxane 
antagonist BM13505 (fig.4). The increase in 
glucose and lactate output were also reduced by 
this inhibitor, to about 45% of the maximal effect. 
(3) 
Fig.4. Inhibition of the C3a-mediated increase of glucose and 
lactate outputs and the reduction of flow by the thromboxane 
A2 antagonist BM13505. (A) Livers were perfused as described 
in fig.2. C3a was infused to a final concentration of 0.4/zg/ml. 
The bars indicate the maximal increase in substrate output or 
decrease in flow. (B) Same conditions as in panel A, except hat 
BM-13505 was infused to a final concentration of 20/~M from 
5 min prior to C3a infusion until the end of the experiments. 
Values are means _+ SE of the number of experiments given in 
parentheses. 
The time course of the change of glucose output 
was not altered by BM13505; however, the lactate 
output remained increased until the end of the ex- 
periment (not shown). 
4. DISCUSSION 
This study showed that the purified human C3a 
anaphylatoxin, the activation peptide of the third 
component of complement, induced an increase in 
glucose and lactate outputs and a reduction in flow 
in perfused rat liver (figs 2A, 3A). It further 
demonstrated that these actions could be an- 
tagonized by the Fab fragments of a C3a-specific 
monoclonal antibody (fig.3B). 
4.1. Mechanism of action of the anaphylatoxin 
C3a 
The thromboxane antagonist BM13505 was 
found to interfere with the action of C3a on liver 
metabolism and hemodynamics (fig.4). This in- 
dicates that the action of C3a was indirect, at least 
in part. The anaphylatoxin might cause a release of 
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thromboxane from non-parenchymal ce ls that in 
turn could cause the increase in glucose and lactate 
outputs and the reduction of flow. This interpreta- 
tion is in accord with the previous finding that 
zymosan-activated rabbit serum caused a release of 
thromboxane from the perfused rabbit liver [5]. 
The interpretation also conforms to the previous 
observation that the thromboxane A2 analogue 
U46619 enhanced gluocose [18-21] and lactate 
[19,20] outputs and reduced flow [19,20] or in- 
creased portal pressure [18,21], respectively. It has 
been reported that guinea-pig peritoneal 
macrophages respond to C3a with a release of 
thromboxane [22]. Thus Kupffer cells which also 
belong to the mononuclear phagocyte system [23] 
might be responsible for the production of throm- 
boxane in the perfusion system used here. 
4.2. Function of the metabolic and hemodynamic 
actions of the anaphylatoxin C3a 
Treatment of C3a with carboxypeptidase to 
remove the C-terminal arginine abolished (fig.2B), 
and the presence of the carboxypeptidase inhibitor 
MERGETPA increased (fig.3A), the observed ef- 
fects of C3a. Apparently the rat liver itself is highly 
capable of inactivating the peptide. This inactiva- 
tion must have occurred very rapidly within the 
vessels of the liver or at the very beginning of the 
sinusoids resulting in the degradation of most of 
the active peptide before it reached the sites of its 
metabolic and hemodynamic a tions. The inactiva- 
tion of C3a by the liver might play an important 
role in its self-protection during systemic genera- 
tion of the anaphylatoxin. The cells at the entrance 
of the sinusoids might act as protecting scavengers 
as proposed previously [24]. Thus, it seems unlike- 
ly that C3a generated systemically in the circula- 
tion has an effect on liver metabolism or 
hemodynamics. In contrast, C3a formed within 
the liver, that is at the site of synthesis of C3, its 
precursor, during inflammatory processes might 
lead to pronounced local metabolic and 
hemodynamic alterations. 
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